28162781|t|Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial
28162781|a|Little evidence-based information is available to guide the treatment of oligoarticular juvenile idiopathic arthritis. We aimed to investigate whether oral methotrexate increases the efficacy of intra-articular corticosteroid therapy. We did this prospective, open-label, randomised trial at ten hospitals in Italy. Using a concealed computer-generated list, children younger than 18 years with oligoarticular - onset disease were randomly assigned (1:1) to intra-articular corticosteroids alone or in combination with oral methotrexate (15 mg/m(2); maximum 20 mg). Corticosteroids used were triamcinolone hexacetonide (shoulder, elbow, wrist, knee, and tibiotalar joints) or methylprednisolone acetate (ie, subtalar and tarsal joints). We did not mask patients or investigators to treatment assignments. Our primary outcome was the proportion of patients in the intention-to-treat population who had remission of arthritis in all injected joints at 12 months. This trial is registered with European Union Clinical Trials Register, EudraCT number 2008-006741-70. Between July 7, 2009, and March 31, 2013, we screened 226 participants and randomly assigned 102 to intra-articular corticosteroids alone and 105 to intra-articular corticosteroids plus methotrexate. 33 (32%) patients assigned to intra-articular corticosteroids alone and 39 (37%) assigned to intra-articular corticosteroids and methotrexate therapy had remission of arthritis in all injected joints (p=0Â·48). Adverse events were recorded for 20 (17%) patients who received methotrexate, which led to permanent treatment discontinuation in two patients (one due to increased liver transaminases and one due to gastrointestinal discomfort). No patient had a serious adverse event. Concomitant administration of methotrexate did not augment the effectiveness of intra-articular corticosteroid therapy. Future studies are needed to define the optimal therapeutic strategies for oligoarticular juvenile idiopathic arthritis. Italian Agency of Drug Evaluation.
28162781	0	15	Intra-articular	T082	C0442108
28162781	16	31	corticosteroids	T121	C3536709
28162781	39	54	intra-articular	T082	C0442108
28162781	55	70	corticosteroids	T121	C3536709
28162781	71	75	plus	T169	C0332287
28162781	76	88	methotrexate	T109,T121	C0025677
28162781	92	136	oligoarticular juvenile idiopathic arthritis	T047	C3898105
28162781	140	151	multicentre	T062	C0206012
28162781	153	164	prospective	T062	C0033522
28162781	166	176	randomised	T062,T170	C0206034
28162781	178	194	open-label trial	T062	C0008976
28162781	245	250	guide	T170	C2825826
28162781	255	264	treatment	T061	C0087111
28162781	268	312	oligoarticular juvenile idiopathic arthritis	T047	C3898105
28162781	326	337	investigate	T169	C1292732
28162781	346	363	oral methotrexate	T200	C1246896
28162781	364	373	increases	T169	C0442805
28162781	378	386	efficacy	T080	C1280519
28162781	390	428	intra-articular corticosteroid therapy	T061	C4054701
28162781	442	453	prospective	T062	C0033522
28162781	455	465	open-label	T062	C0008976
28162781	467	483	randomised trial	T062,T170	C0206034
28162781	491	500	hospitals	T073,T093	C0019994
28162781	504	509	Italy	T083	C0022277
28162781	519	528	concealed	T080	C0443189
28162781	529	552	computer-generated list	T170	C0745732
28162781	554	562	children	T100	C0008059
28162781	563	575	younger than	T033	C2237067
28162781	579	584	years	T079	C1510829
28162781	590	604	oligoarticular	T082	C0439754
28162781	607	620	onset disease	T079	C0277793
28162781	626	634	randomly	T080	C0439605
28162781	635	643	assigned	T169	C1516050
28162781	653	668	intra-articular	T082	C0442108
28162781	669	684	corticosteroids	T121	C3536709
28162781	685	690	alone	T081	C0205171
28162781	694	713	in combination with	T080	C0205195
28162781	714	731	oral methotrexate	T200	C1246896
28162781	745	752	maximum	T081	C0806909
28162781	761	776	Corticosteroids	T121	C3536709
28162781	787	813	triamcinolone hexacetonide	T109,T121	C0077004
28162781	815	823	shoulder	T030	C0037009
28162781	825	830	elbow	T030	C0013770
28162781	832	837	wrist	T030	C1322271
28162781	839	843	knee	T030	C0022745
28162781	849	866	tibiotalar joints	T030	C0003087
28162781	871	897	methylprednisolone acetate	T109,T121	C0600901
28162781	903	911	subtalar	T030	C0038593
28162781	916	929	tarsal joints	T030	C1527245
28162781	948	956	patients	T101	C0030705
28162781	960	973	investigators	T097	C0008961
28162781	977	986	treatment	T061	C0087111
28162781	987	998	assignments	T169	C1516050
28162781	1004	1019	primary outcome	T169	C1274040
28162781	1028	1038	proportion	T081	C1709707
28162781	1042	1050	patients	T101	C0030705
28162781	1058	1076	intention-to-treat	T062	C2718028
28162781	1077	1087	population	T098	C1257890
28162781	1096	1105	remission	T033	C0544452
28162781	1109	1118	arthritis	T047	C0003864
28162781	1126	1134	injected	T061	C0021485
28162781	1135	1141	joints	T030	C0022417
28162781	1148	1154	months	T079	C0439231
28162781	1161	1166	trial	T062	C0008976
28162781	1170	1180	registered	T058	C1514821
28162781	1186	1225	European Union Clinical Trials Register	T058	C1254363
28162781	1227	1241	EudraCT number	T170	C0282574
28162781	1266	1270	July	T080	C3829447
28162781	1284	1289	March	T079	C3829202
28162781	1303	1311	screened	T169	C2348582
28162781	1316	1328	participants	T098	C0679646
28162781	1333	1341	randomly	T080	C0439605
28162781	1342	1350	assigned	T169	C1516050
28162781	1358	1373	intra-articular	T082	C0442108
28162781	1374	1389	corticosteroids	T121	C3536709
28162781	1390	1395	alone	T081	C0205171
28162781	1407	1422	intra-articular	T082	C0442108
28162781	1423	1438	corticosteroids	T121	C3536709
28162781	1439	1443	plus	T169	C0332287
28162781	1444	1456	methotrexate	T109,T121	C0025677
28162781	1467	1475	patients	T101	C0030705
28162781	1476	1484	assigned	T169	C1516050
28162781	1488	1503	intra-articular	T082	C0442108
28162781	1504	1519	corticosteroids	T121	C3536709
28162781	1520	1525	alone	T081	C0205171
28162781	1539	1547	assigned	T169	C1516050
28162781	1551	1566	intra-articular	T082	C0442108
28162781	1567	1582	corticosteroids	T121	C3536709
28162781	1587	1599	methotrexate	T109,T121	C0025677
28162781	1600	1607	therapy	T061	C0087111
28162781	1612	1621	remission	T033	C0544452
28162781	1625	1634	arthritis	T047	C0003864
28162781	1642	1650	injected	T061	C0021485
28162781	1651	1657	joints	T030	C0022417
28162781	1668	1682	Adverse events	T046	C0877248
28162781	1710	1718	patients	T101	C0030705
28162781	1732	1744	methotrexate	T109,T121	C0025677
28162781	1759	1768	permanent	T079	C0205355
28162781	1769	1778	treatment	T061	C0087111
28162781	1779	1794	discontinuation	T033	C1444662
28162781	1802	1810	patients	T101	C0030705
28162781	1823	1852	increased liver transaminases	T033	C1848701
28162781	1868	1895	gastrointestinal discomfort	T184	C1096250
28162781	1898	1900	No	T033	C1513916
28162781	1901	1908	patient	T101	C0030705
28162781	1915	1922	serious	T080	C0205404
28162781	1923	1936	adverse event	T046	C0877248
28162781	1938	1964	Concomitant administration	T169	C2826730
28162781	1968	1980	methotrexate	T109,T121	C0025677
28162781	1989	1996	augment	T169	C0442805
28162781	2001	2014	effectiveness	T080	C1280519
28162781	2018	2056	intra-articular corticosteroid therapy	T061	C4054701
28162781	2058	2072	Future studies	T062	C2603343
28162781	2098	2105	optimal	T080	C2698651
28162781	2106	2128	therapeutic strategies	T061	C0087111
28162781	2133	2177	oligoarticular juvenile idiopathic arthritis	T047	C3898105
28162781	2179	2212	Italian Agency of Drug Evaluation	T092	C1561598